NEWS - Jul 29, 2019 Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression Read more
NEWS - Jun 3, 2019 Relmada Therapeutics to Present at LD Micro Invitational Conference in Los Angeles Read more
NEWS - May 31, 2019 Relmada Therapeutics Presents Development Program of REL1017 for Treatment of Depression at the 2019 American Society of Clinical Psychopharmacology Meeting Read more
NEWS - Apr 16, 2019 Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results Read more
NEWS - Apr 3, 2019 Gina DiGuglielmo Joins Relmada as Vice President and Head of Clinical Operations Read more
NEWS - Dec 12, 2018 Relmada Therapeutics Presents Clinical Data on Increased BDNF Plasma Levels in Subjects Treated with REL-1017 Read more
NEWS - Oct 2, 2018 Relmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels Read more
NEWS - Sep 18, 2018 Relmada Therapeutics Provides Enrollment Update in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder Read more
NEWS - Aug 9, 2018 Relmada Therapeutics Allowed Patent Application in China Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms Read more
